Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.

Oncology reports

Volumn 6, Issue 2, 1999, Pages 421-426

  Mantovani, G ^a   Ghiani, M ^a   Curreli, L ^a   Maccio, A ^a   Massa, D ^a   Succu, G ^a   Lai, P ^a   Massa, E ^a   Mudu, M C ^a   Astara, G ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKINE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD; BLOOD TRANSFUSION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; ESOPHAGUS TUMOR; FEMALE; HEAD AND NECK TUMOR; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CISPLATIN; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; ESOPHAGEAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

MLCS; MLOWN;

EID: 0033091513     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.6.2.421     Document Type: Article

References (0)